American Association for Cancer Research
15417786mcr130246t-sup-meth.pdf (112.84 kB)

Supplementary Methods from The Impact of miRNA-Based Molecular Diagnostics and Treatment of NRF2-Stabilized Tumors

Download (112.84 kB)
journal contribution
posted on 2023-04-03, 16:07 authored by Shinsuke Yamamoto, Jun Inoue, Tatsuyuki Kawano, Ken-ichi Kozaki, Ken Omura, Johji Inazawa

PDF file - 112K



NF-E2–related factor 2 (NRF2) is a master transcriptional regulator that integrates cellular stress responses and is negatively regulated by Kelch-like ECH-associated protein 1 (KEAP1) at the posttranslational level. In human cancers, aberrantly stabilized NRF2, either by mutation of NRF2 or KEAP1, plays a vital role in chemoresistance and tumor cell growth through the transcriptional activation of target genes, suggesting that targeted inhibition of NRF2 is a potential therapy for NRF2-stabilized tumors. MicroRNAs (miRNA) are endogenous small noncoding RNAs that can negatively regulate gene expression by interfering with the translation or stability of target transcripts. Moreover, tumor-suppressor miRNAs have been suggested to be useful for cancer treatment. Here, a reporter-coupled miRNA library screen identified four miRNAs (miR-507, -634, -450a, and -129-5p) that negatively regulate the NRF2-mediated oncogenic pathway by directly targeting NRF2. Importantly, downregulation of these miRNAs, in addition to the somatic mutation of NRF2 or KEAP1, is associated with stabilized NRF2 and poor prognosis in esophageal squamous cell carcinoma (ESCC). Furthermore, administration of a miR-507 alone or in combination with cisplatin inhibited tumor growth in vivo. Thus, these findings reveal that miRNA-based therapy is effective against NRF2-stabilized ESCC tumors.Implications: This study determines the potential of miRNA-based molecular diagnostics and therapeutics in NRF2-stablized tumors. Mol Cancer Res; 12(1); 58–68. ©2013 AACR.

Usage metrics

    Molecular Cancer Research



    Ref. manager